Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Miragen Therapeutics Inc (MGEN)

Miragen Therapeutics Inc (MGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team Globe NewsWire - Tue Jan 19, 2021

BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc....

MGEN : 23.01 (-0.09%)
miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease Globe NewsWire - Thu Dec 17, 2020

Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology

MGEN : 23.01 (-0.09%)
miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates Globe NewsWire - Tue Nov 10, 2020

BOULDER, Colo., Nov. 10, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a biotechnology company advancing new treatments for patients with diseases that are underserved by current...

MGEN : 23.01 (-0.09%)
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc. Globe NewsWire - Wed Oct 28, 2020

Acquisition includes clinical stage anti-IGF - 1R monoclonal antibody, VRDN-001 , intended for the treatment of thyroid eye disease (TED)

MGEN : 23.01 (-0.09%)
miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL) Globe NewsWire - Mon Oct 5, 2020

miRagen decides to discontinue further internal development of cobomarsen

MGEN : 23.01 (-0.09%)

Barchart Exclusives

How Surging AI Demand Could Drive This Dividend Stock Higher Barchart - Thu Sep 19, 6:30PM CDT
Eaton, a diversified power management company, is poised to benefit from the surging demand for AI-driven data centers, with its innovative power solutions and strong dividend growth making it an attractive investment opportunity. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot